assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before June 19, 1995, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: May 9, 1995.

George H. Pauli,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 95–12296 Filed 5–18–95; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 95N–0127]

Roussel Corp., et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 16 abbreviated new drug applications (ANDA's). The holders of the ANDA's notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

EFFECTIVE DATE: June 19, 1995.

FOR FURTHER INFORMATION CONTACT: Lola E. Batson, Center for Drug Evaluation and Research (HFD–360), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1038.

SUPPLEMENTARY INFORMATION: The holders of the ANDA's listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their request, waived their opportunity for a hearing.

ANDA no.	Drug	Applicant
62–830	Sterile Cefazolin Sodium, U.S.P. (bulk)	Roussel Corp., 95 Chestnut Ridge Rd., P.O. Box 30, Montvale, NJ 07645.
70–662	Diazepam Injection, U.S.P., 5 milligrams (mg)/milliliter (mL)	Fujisawa Pharmaceutical Co., Parkway North Center, Three Parkway North, Deerfield, IL 60015–2548.
80–517	Prednisolone Sodium Phosphate Injection, U.S.P., 20 mg/mL	Steris Laboratories, Inc., 620 North 51st Ave., Phoenix, AZ 85043–4705.
80–702	Vitamin A Palmitate Capsules, EQ 50,000 Units Base	Banner Pharmacaps, Inc., 1111 Jefferson Ave., Elizabeth, NJ 07207.
83–531	Dimenhydrinate Injection, U.S.P., 50 mg/mL	Steris Laboratories, Inc.
83–593	Chlorpheniramine Maleate Injection, U.S.P., 10 mg/mL	Do.
83–948	Vitamin A Palmitate Capsules, EQ 50,000 Units Base	Banner Pharmacaps, Inc.
83–973	Vitamin A Capsules, 50,000 U.S.P. Units	Do.
85–591	Chlorpromazine Hydrochloride Injection, U.S.P., 25 mg/mL	Steris Laboratories, Inc.
86–419	Testosterone Injection, U.S.P., 50 mg/mL	Do.
86–420	Testosterone Injection, U.S.P., 25 mg/mL	Do.
86–468	Procainamide Hydrochloride Extended-release Tablets, U.S.P., 250 mg.	Parke-Davis, Division of Warner-Lambert Co., 2800 Plymouth Rd., Ann Arbor, MI 48105.
86–844	Acetic Acid Otic Solution with Hydrocortisone, 2%/1%	Procter & Gamble Pharmaceuticals, 11370 Reed Hartman Hwy. Cincinnati, OH 45241–2422.
86–845	Acetic Acid Otic Solution, U.S.P., 2%	Do.
87–274	Hydroxyzine Hydrochloride Injection, U.S.P., 25 mg/mL and 50 mg/mL.	Steris Laboratories, Inc.
88–642	Diethylpropion Hydrochloride Tablets, U.S.P., 25 mg	Lemmon Co., 650 Cathill Rd., Sellersville, PA 18960.

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the ANDA's listed above, and all amendments and supplements thereto, is hereby withdrawn, effective June 19, 1995.

Dated: April 18, 1995.

Murray M. Lumpkin,

Deputy Director, Center for Drug Evaluation and Research.

[FR Doc. 95–12295 Filed 5–18–95; 8:45 am]

BILLING CODE 4160–01–F

Public Health Service

Agency Forms Undergoing Paperwork Reduction Act Review

Each Friday the Public Health Service (PHS) publishes a list of information collection requests under review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the PHS Reports Clearance Office on (202) 690–7100.

The following requests have been submitted for review since the list was last published on May 12.

1. Studies of Adverse Reproductive Outcomes in Female Occupational Groups—New—The reproductive health of a group of female workers exposed to a particular environmental chemical agent will be compared to the reproductive health of a group of working women with no occupational exposure to known or suspected reproductive toxicants. Respondents: Individuals or households; Business or other for-profit. Send comments to Shannah Koss, Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503.

	No. of respondents	No. of responses per respondent	Avg. burden/response
Women ..	6,200	1	2.85 hours.
Physicians.	1,200	1	.5 hour.

Estimated Annual Burden: 18,250 hours.

2. Infant Feeding Study Puberty Follow-up—0925–0381—Extension, no change—Children from a previous study of health effects of PCBs and DDE are being restudied to determine whether PCBs or DDE affect growth or pubertal development. Information is being collected annually from 431 children and their parents to determine whether there is public health concern about these chemicals in children. Respondents: Individuals or households; Number of Respondents: 862; Number of Responses per Respondent: 1.1; Average Burden per Response: 0.23 hour; Estimated Annual Burden: 219 hours. Send comments to James Scanlon, Office of the Assistant Secretary for Health, Room 737–F, Humphrey Building, 200 Independence Ave., SW., Washington, DC 20201.

3. FDA Recall Regulations—0910–0249—Extension, no change—Recall guidelines set forth procedures to be used by manufacturers and distributors or other responsible persons in notifying or alerting health professionals or other persons of an unreasonable risk of substantial harm to the public's health and describe the procedures used or required by FDA in the recall process. Respondents: Business or other for-profit. Send comments to Shannah Koss, Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503.

	No. of respondents	No. of responses/respondents	Avg. burden/response
21 CFR 7.42.	1,294	1	1.8 hours.
21 CFR 7.46/ 7.49.	1,294	1	4 hours.
21 CFR 7.53.	1,294	1	36 hours.
21 CFR 7.55(b).	1,294	1	2 hours.

Estimated Annual Burden: 56,677 hours.

Written Comments and recommendations concerning the proposed information collections should be sent within 30 days of this notice directly to the individual designated.

Dated: May 12, 1995.

James Scanlon,

Director, Data Policy Staff, Office of the Assistant Secretary for Health and PHS Report Clearance Officer.

[FR Doc. 95–12256 Filed 5–18–95; 8:45 am]

BILLING CODE 4160–01–M

Substance Abuse and Mental Health Services Administration

Advisory Committee for Women's Services; Meeting

Pursuant to Pub.L. 92–463, notice is hereby given of the meeting of the Advisory Committee for Women's Services of the Substance Abuse and Mental Health Services Administration (SAMHSA).

The meeting of the Advisory Committee for Women's Services will include a discussion of policy and program issues relating to women's substance abuse and mental health service needs at SAMHSA, including the SAMHSA FY 1996 budget, the SAMHSA Strategic Plan, and on-going women's activities within SAMHSA's Center for Substance Abuse Prevention, Center for Substance Abuse Treatment and Center for Mental Health Services.

A summary of the meeting and/or a roster of committee members may be obtained from: Jennifer B. Fiedelholtz, Executive Secretary, Advisory Committee for Women's Services, Office for Women's Services, Substance Abuse and Mental Health Services Administration, Parklawn Building, Room 13–99, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone: (301) 443–5184.

Substantive information may be obtained from the contact whose name and telephone number is listed below.

Committee Name: Advisory Committee for Women's Services.

Meeting Date: June 12–13, 1995.

Place: Conference Room B, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857.

Open: 8:30 a.m. to 5 p.m.

Contact: Jennifer B. Fiedelholtz, Room 13–99, Parklawn Building, Telephone (301) 443–5184.

Dated: May 15, 1995.

Jeri Lipov,

Committee Management Officer, Substance Abuse and Mental Health Services Administration.

[FR Doc. 95–12331 Filed 5–18–95; 8:45 am]

BILLING CODE 4162–20–P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

Office of the Assistant Secretary for Community Planning and Development

[Docket No. N–95–1917; FR–3778–N–37]

Federal Property Suitable as Facilities To Assist the Homeless

AGENCY: Office of the Assistant Secretary for Community Planning and Development, HUD.

ACTION: Notice.

SUMMARY: This Notice identifies unutilized, underutilized, excess, and surplus Federal property reviewed by HUD for suitability for possible use to assist the homeless.

ADDRESSES: For further information, contact David Pollack, room 7256, Department of Housing and Urban Development, 451 Seventh Street SW, Washington, DC 20410; telephone (202) 708–1234; TDD number for the hearing- and speech-impaired (202) 708–2565 (these telephone numbers are not toll-free), or call the toll-free Title V information line at 1–800–927–7588.

SUPPLEMENTARY INFORMATION: In accordance with 56 FR 23789 (May 24, 1991) and section 501 of the Stewart B. McKinney Homeless Assistance Act (42 U.S.C. 11411), as amended, HUD is publishing this Notice to identify Federal buildings and other real property that HUD has reviewed for suitability for use to assist the homeless. The properties were reviewed using information provided to HUD by Federal landholding agencies regarding unutilized and underutilized buildings and real property controlled by such agencies or by GSA regarding its inventory of excess or surplus Federal property. This Notice is also published in order to comply with the December 12, 1988 Court Order in *National Coalition for the Homeless* v. *Veterans Administration,* No 88–2503–OG (D.D.C.).

Properties reviewed are listed in this Notice according to the following categories: Suitable/available, suitable/unavailable, suitable/to be excess, and unsuitable. The properties listed in the three suitable categories have been reviewed by the landholding agencies, and each agency has transmitted to HUD: (1) Its intention to make the property available for use to assist the homeless, (2) its intention to declare the property excess to the agency's needs, or (3) a statement of the reasons that the property cannot be declared excess or made available for use as facilities to assist the homeless.